Biblio

Author Title [ Type

] Year

Filters: Author is Dreyling, Martin [Clear All Filters]

Journal Article

Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, et al. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia. 2024.

Fischer L, Jiang L, Bittenbring JThomas, Huebel K, Schmidt C, Duell J, Metzner B, Krauter J, Glass B, Huettmann A, et al. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis. Ann Hematol. 2023.

Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower C, Freeman CL, et al. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv. 2022.

von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. The Diagnosis and Treatment of Primary CNS Lymphoma. Dtsch Arztebl Int. 2018;115115(25):419-426.

Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.

Alig S, Jurinovic V, Esfahani MShahrokh, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Adv. 2020;4(18):4451-4462.

Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2022:JCO2201780.

Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomis. Lancet. 2024.

Rusconi C, Cheah CY, Eyre TAndrew, Tucker DL, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, et al. Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022.

Metzner B, Müller TH, Casper J, Kimmich C, Köhne C-H, Petershofen E, Renzelmann A, Thole R, Voss A, Dreyling M, et al. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol. 2023.

Zoellner A-K, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648-e657.

Macintyre E, Döhner K, Grønbæk K, Dreyling M, Huntly B, Almeida A, Gribben J. Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine. Hemasphere. 2024;8(4):e65.

Scheubeck G, Hoffmann M, Jurinovic V, Fischer L, Unterhalt M, Schmidt C, Böck H-P, Dührsen U, Kaesberger J, Kremers S, et al. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Ann Hematol. 2024.

Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, Truemper L, Held G, Bentz M, Borchmann P, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021.

Salles G, Duell J, Barca EGonzález, Tournilhac O, Jurczak W, Liberati AMarina, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020.